Spots Global Cancer Trial Database for figo grade 2 endometrial endometrioid adenocarcinoma

Every month we try and update this database with for figo grade 2 endometrial endometrioid adenocarcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer	NCT04092270	Endometrial Hig... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... FIGO Grade 1 En... FIGO Grade 2 En... Ovarian High Gr... Ovarian Seromuc... Ovarian Undiffe... Platinum-Sensit... Primary Periton... Primary Periton... Primary Periton... Primary Periton... Recurrent Fallo... Recurrent Low G... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Prima... Recurrent Prima...	Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Pegylated Lipos... Peposertib	18 Years -	National Cancer Institute (NCI)
Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer	NCT03018249	FIGO Grade 1 En... FIGO Grade 2 En... FIGO Grade 3 En...	Entinostat Hysterectomy Laboratory Biom... Medroxyprogeste...	18 Years -	National Cancer Institute (NCI)
Prediction of Recurrence Among Low Risk Endometrial Cancer Patients	NCT04604613	FIGO Grade 1 En... FIGO Grade 2 En...	Bilateral Salpi... Biospecimen Col... Hysterectomy Laboratory Biom... Lymph Node Mapp... Sentinel Lymph ...	-	M.D. Anderson Cancer Center
Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer	NCT03018249	FIGO Grade 1 En... FIGO Grade 2 En... FIGO Grade 3 En...	Entinostat Hysterectomy Laboratory Biom... Medroxyprogeste...	18 Years -	National Cancer Institute (NCI)
Prediction of Recurrence Among Low Risk Endometrial Cancer Patients	NCT04604613	FIGO Grade 1 En... FIGO Grade 2 En...	Bilateral Salpi... Biospecimen Col... Hysterectomy Laboratory Biom... Lymph Node Mapp... Sentinel Lymph ...	-	M.D. Anderson Cancer Center
Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers	NCT05538897	FIGO Grade 1 En... FIGO Grade 2 En... Metastatic Endo... Recurrent Endom... Stage IV Uterin...	Biospecimen Col... Computed Tomogr... Ipatasertib Magnetic Resona... Megestrol Aceta...	18 Years -	National Cancer Institute (NCI)
Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer	NCT02397083	Atypical Endome... FIGO Grade 1 En... FIGO Grade 2 En...	Everolimus Laboratory Biom... Levonorgestrel-...	18 Years -	M.D. Anderson Cancer Center
Remote Home-Based Exercise Program for Strength Training in Endometrial Cancer Survivors in Rural Areas	NCT06213571	FIGO Grade 1 En... FIGO Grade 2 En... Stage IA Uterin... Stage IB Uterin...	Exercise Counse... Exercise Interv... Health Promotio... Interview Physical Perfor... Questionnaire A... Telemedicine	50 Years -	Mayo Clinic
Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer	NCT02397083	Atypical Endome... FIGO Grade 1 En... FIGO Grade 2 En...	Everolimus Laboratory Biom... Levonorgestrel-...	18 Years -	M.D. Anderson Cancer Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: